As we know, kidney has a very conspicuous ability of compensation. At the onset of chronic kidney disease, little symptoms may occur which cannot trigger your attention. Once you feel discomfort or obvious symptoms emerge, your conditions are usually in a End Stage Renal Disease(ESRD). The most common method to treat End Stage Renal Failure(ESRF) is either dialysis or kidney transplant in clinical practices. And both of them would cause great injury to patients and incur great economic loss to their families virtually, furthermore, the survival time of most transplanted kidney is very short. It is inevitable to see such a tragedy that patients pass away and financial deficit appear.
Every medical staff and institution have the responsibility to deter the happening of this tragedy, so do we. After years of efforts, we succeed in innovating Micro-Chinese Medicine Osmotherapy. Massive clinical practices prove this therapy of external application to be effective in blocking renal fibrosis, repairing damaged nephrons and recovering renal function. Meantime, we bring in Immunotherapy technology, the primitive undifferentiated cells can be extracted and be injected into human body. Under the stimulation of damaging signals, Immunotherapys can move toward those damaged areas, and then differentiate into requisite tissues and organs. In other words, Immunotherapys are capable to repair those damaged cells. During the whole treatment, Immunotherapys are transfused into human body through intravenous injection which causes little trauma and suffering to human body. Moreover, this treatment does not require a strict cell-matching and blood-type matching. Furthermore, no rejection would come across because of its low immunogenicity. Thus Immunotherapy can better repair the injured nephrons and restore the damaged renal function.
The combination of Micro-Chinese Medicine Osmotherapy (MCMO) and Immunotherapy (SCT) have attained striking effect on treating Chronic Kidney Disease(CKD Stage 3 Treatment and CKD Stage 4 Treatment) . MCMO can block the renal fibrosis and build a favorable environment for ensuing treatment. SCT can provide fresh cells for damaged tissue and nephrons. In this case, improving kidney function can be achieved and patients do not need to endure dialysis and complications caused by using immunosuppressive medicines.
